Aldeyra Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
131 HARTWELL AVENUE, LEXINGTON, MA, 02421
Mailing Address
131 HARTWELL AVENUE, LEXINGTON, MA, 02421
Phone
781-761-4904
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$33.85M
Net Income
$104.61M
Total Assets
$33.60M
Total Liabilities
$70.04M
Cash & Equivalents
$-0.56
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 10-K Annual financial report | February 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
Annual Reports
10-K
February 27, 2026
- Aldeyra plans to resubmit the New Drug Application (NDA) for reproxalap in DED in Q2 2026, with a potential PDUFA date in Q4 2026.
- The company concluded FY2025 with approximately $120 million in cash, providing a projected cash runway into Q3 2027.
Material Events
8-K
Other
March 17, 2026
High Impact
- FDA did not raise safety or manufacturing concerns for reproxalap, focusing solely on effectiveness.
- Aldeyra plans to request a 'Type A meeting' with the FDA to discuss concerns and clarify requirements for potential approval.
8-K
Other
December 16, 2025
High Impact
- The U.S. FDA has extended the review period for Aldeyra Therapeutics' dry eye drug, Reproxalap.
- This extension delays the potential approval and launch of Reproxalap, creating significant uncertainty for the company.
Insider Trading
BUY
2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.